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Introduction
Quantification is a particularly important aspect of biomarker discovery: Protein biomarkers such as prostate specific antigen (PSA) and C-reactive protein (CRP) are typically present in samples from both healthy and diseased donors [1] . Thus, biomarker discovery not only requires 3 reliable protein identification but also quantification. The current trend of using collections or panels of several proteins as biomarkers further increases the need for accurate quantification.
Unfortunately, the intensity of a peak in a mass spectrum alone cannot be used to measure the absolute level of the corresponding peptide or protein. This is due to the fact that peak intensity depends on peptide-specific factors such as ionization efficiency. Thus, mass spectrometry-based proteomics is intrinsically not quantitative. However, over the last decade several strategies have been developed that enable quantification on a global proteomic scale [2] [3] [4] [5] . The general principle of these strategies is that relative changes in the intensity of a peak rather than its absolute intensity are used for quantification. This can be done by comparing the intensities of the same peptide across different runs ("label free" quantification).
Alternatively, peptides can be labeled with heavy stable isotopes ("stable isotope labeling" or SIL). Mass spectrometry can distinguish such heavy-labeled peptides from their normal (i.e. light) counterparts due to their mass difference, meaning that differentially-labeled samples can be mixed and analyzed together in a single run. This gives rise to pairs of physicochemically identical peptides of different isotope composition. The ratio of peak intensities of such peptide pairs accurately reflects relative changes in the abundance of the corresponding peptides. Due to the fact that samples are mixed before digestion, SIL-based approaches are more robust and generally considered more precise than label-free methods where samples are processed in parallel.
A particularly powerful approach for SIL-based quantification is stable isotope labeling with amino acids in cell culture (SILAC) [6] . Reviewing the huge field of SILAC-based proteomics is 4 beyond the scope of this manuscript; we refer the interested reader to a number of excellent reviews [7] [8] [9] [10] . Here, we will present selected examples on how SILAC-based strategies are currently used for biomarker discovery which we considered particularly informative. Since dozens of papers with this topic have been published our selection will inevitably be incomplete, and we apologize to the colleagues whose work could not be included. We will also discuss how SILAC can be used to obtain information about the absolute abundance of proteins -an aspect that is particularly relevant for mathematical modeling of diseases. Let us begin with a brief introduction to SILAC.
A brief history of SILAC
As a metabolic labeling technique, SILAC has its roots in the pioneering work of Rudolf Schoenheimer. He realized in 1935 that isotopes can be employed to label a physiological substance in such a way that the "the animal organism will not be able to differentiate between them" while the chemist is able to "distinguish and to estimate them in small quantities" [11] .
Since then, growth media in which all atoms of a specific element are replaced by their heavy isotopes have been employed in many studies. For example, the Chait lab used 15 N substituted medium to quantify phosphorylation in yeast [12] and the Heck lab established 15 N labeling in two additional model organisms, C. elegans and D. melanogaster [13] . Although these labeling approaches allowed for global protein quantification in various model organisms, they also have several disadvantages. First, With more than 2,000 citations of the landmark SILAC paper, the method is one of the most popular approaches for expression proteomics, and has been employed to answer a wide range of questions in diverse areas of biomedical research [7] . The most significant advantage is that SILAC is more accurate than either label-free quantification or chemical labeling approaches [14] [15] [16] , due to the fact that differentially labeled samples can be combined very early in the workflow, minimizing errors introduced during sample handling. SILAC is particularly advantageous in situations where samples are extensively processed, such as fractionation and affinity-based enrichment of peptides with post-translational modifications. Furthermore, due to the high accuracy of SILAC, the method yields high quality data even for single peptides. This is particularly beneficial for analysis of posttranslational modifications which have to be quantified at the peptide level. For this reason, SILAC is particularly popular for phosphoproteomics [17] [18] [19] . Moreover, since SILAC is a metabolic labeling method, it can also be employed to quantify protein dynamics by measuring the rate of isotope incorporation. For example, dynamic SILAC can quantify protein turnover and pulsed SILAC can measure changes in protein synthesis on a proteome-wide scale [20] [21] [22] .
SILAC for patient-derived samples: the spike-in approach
As the name indicates, SILAC was designed specifically to label cells in culture. However, metabolic labeling with amino acids can also be used to label entire organisms (for an overview see Kirchner and Selbach [23] ). The approach has been used to create an entire SILAC zoo, ranging from lower eukaryotes 7 like baker's yeast [24] via worms [25] and flies [14] up to mice [26] . Here, the naturally-occurring auxotrophies are used and the light lysine amino acid is replaced with its heavy counterpart. Long labeling times and special diet requirements preclude this technique from use on human beings, so alternate techniques must be used for the introduction of isotopic labels into human-derived samples. A number of post-lysis labeling methods have been well-established (e.g. dimethylation of lysines [27] or iTRAQ labeling of peptide amino groups [28] ), although such approaches introduce significantly more variation into the system relative to metabolic labeling techniques, which allows mixing of the samples early in the biochemical preparation process. All variations in lysis efficiency, biochemical preparations etc. can thus be neglected [2, 16] .
Although SILAC cannot be used to directly label humans, the development of SILAC spike-in methods samples. The idea of using cell culture-derived reference standards for quantification was first applied for quantitative proteomics in mouse brain [29] and has since become a popular experimental design for SILAC experiments.
The spike-in method, while allowing the quantification of patient samples, introduces more variability to the analysis in comparison to labeling in cell culture. Mixing the standard and the sample late in the preparation does not compensate for differences in lysis and extraction efficiency. In addition, the protein composition of the standard is itself problematic; in order to quantify the proteins present in the sample the protein has to be present in the labeled standard. If the protein is not detectable in the 8 standard, SILAC-based quantification is impossible. Furthermore, SILAC is most accurate when the abundance of differentially labeled peptide pairs is similar i.e. same order of magnitude. The ideal reference standard, therefore, contains all proteins that are present in the clinical sample at an abundance similar to their physiological levels. These considerations led to the development of the Super-SILAC method [30] . Here the concept is that different cell lines are curated and combined in a way to best represent the sample of interest. In order to prepare the best possible reference standard several cell lines originating from different tissues are labeled and compared in an initial experiment with the complexity of the patient sample. The tailored combination of cell lines representing most of the proteins is used for the subsequent quantification steps. It is probably impossible or impractical to design a cell line reference standard that would be a perfect match to the tissue. However, the Super-SILAC approach has been shown to reduce the dynamic range of log2 fold changes between the reference standard and the tissue [30] . This increases the accuracy and precision of quantification, even though combining several cell lines increases the complexity of the heavy standard.
SILAC and biomarkers: current applications
Although the applications of SILAC-based proteomics for biomarker discovery are quite diverse, more than half of the studies focused on cancer. This is not surprising because early diagnosis is critical for the success of therapeutic intervention [31] . The human plasma proteome holds the promise of revolutionizing early diagnosis once the characteristic proteins indicative of a specific disease are known.
However, protein concentrations in plasma span a dynamic range of more than ten orders of magnitude, posing a major challenge to proteomic discoveries [1] . This is probably reflected in the fact that no single biomarker identified and validated by proteomics has found its way into clinical practice [32] . A current trend is to focus on subproteomes such as secreted proteins (secretome), or on specific proteins of interest with targeted (as opposed to global) MS approaches. Rather than reviewing all of the different 9 SILAC-based studies for biomarker discovery we will focus on the analysis of secretomes as well as targeted approaches.
Secreted proteins are particularly attractive for biomarker discovery. As their name indicates, these proteins are released from cells into the surrounding matrix and are thus detectable in biological fluids such as plasma. Additionally the secretion pattern is changed when a cell is transformed to a cancer cell [33] . So a number of studies used SILAC-based quantitative proteomics to identify proteins secreted from different kinds of cancer cells. For example, proteomic comparisons of neoplastic and nonneoplastic pancreatic cells led to the identification of more than 100 proteins that are preferentially secreted by neoplastic cells, with similar results obtained recently for gastric cancer [34, 35] . SILAC-based proteomics was also used to characterize proteins secreted from metastatic and non-metastatic colon cancer cells [36] . In such studies, secreted proteins are identified from cell culture experiments and not directly in plasma. Instead, Yu and co-workers used secreted proteins derived from heavy-labeled pancreatic cancer cells to generate a reference standard [37] . Spiking this reference standard into sera from pancreatic cancer patients and into control sera allowed them to identify proteins upregulated in cancer. A study from the Mann lab combined the super-SILAC approach with biochemical enrichment of N-glycosylated peptides from breast cancer cell lines [38] . Since the secretome profiles correctly clustered different cancer stages and corresponding glycopeptides were also detectable in human serum, this appears to be a promising strategy for finding the hallmarks of an underlying pathology. In a study using labeled cells as a spike-in standard, Montaldo et al. identified vimentin as a new biomarker for the diagnosis of liver fibrosis after HCV infection [39] .
All techniques described so far are true shotgun proteomic techniques, capable of quantifying thousands of different proteins in one experiment. For many studies this is not really necessary, since the main targets are already well-characterized and the pathways involved have been identified. Here the combination of the SILAC labeling and immunoprecipitation techniques provides a unique approach to identify new biomarkers. Cell lines are labeled with the SILAC technique and the protein target of the analysis is precipitated using a specific antibody, with co-precipitated material then subjected to a shotgun mass spectrometric analysis. The aim is to identify the complete interactome of the target and the ratio of the heavy signal to the light one can be used to identify specific interactors vs. nonspecific binders. This allowed Paweletz and coworkers to identify new phosphorylations sites that are responsive to different PDK1 inhibitors [40] . In a related study, Andersen and colleagues identified 71 regulated Phospho-sites of the PI3K pathway using a similar approach [41] .
Selected reaction monitoring (SRM) has been used as a method for absolute quantification of proteins [42] , usually on a small scale due to the relative laborious setup of the technique in comparison to shot-gun based quantifications [43, 44] . Here the known mass of a peptide is selected from the complex proteomic sample, fragmented followed by the selection of specific fragment ions. For the quantification of the target heavy labeled peptides are added to the proteomic preparation, serving as a reference of know concentration. A variation of this approach and an alternative to biochemical enrichment, SILAC-based quantification can also be used in SRM-type analysis, with a heavy SILAC spikein standard used as the reference in a classical SRM experiment. While the full potential of this approach remains to be explored, data from Liu and co-workers indicated that the method can be employed to reproducibly quantify 17 breast cancer-related focal adhesion proteins [15] . On the one hand, the advantage of this set-up is that SILAC can generate tens of thousands of isotopically labeled peptides at minimal costs. On the other, the method only allows for relative quantification, since the absolute amounts of the reference proteins spiked-in are unknown. A current development from the Uhlen and numbers is an overarching goal in our pursuit of understanding.
In conclusion, SILAC-based approaches have been successfully used in a number of biomarker studies.
Compared to other methods, SILAC-based quantification has the unique advantage of low experimental variability. In the future, the widespread availability of high-resolution mass spectrometers and automated data processing pipelines will further advance biomarker discovery. Eventually, this may bring mass spectrometers to the doctor's office -the dream of early pioneers like John Fenn. 
